Biocon gets Health Canada nod for denosumab in 2026

What Health Canada approved and when

Biocon Ltd. said Health Canada has granted approval for two denosumab biosimilars, Bosaya and Vevzuo, dated April 3, 2026. Denosumab is used in bone health settings, including osteoporosis and bone complications associated with cancer. Biocon described the approvals as a step that expands access to its biologic therapies in a key North American market. The company also positioned the products as more affordable treatment options for Canadian patients. The announcement adds to Biocon’s recent Canada approvals in immunology and ophthalmology through its biosimilars business.

Bosaya and Vevzuo: the patient groups highlighted

Biocon said the denosumab approvals are expected to benefit over 2 million adults with osteoporosis. It also referenced “hundreds of cancer patients with bone metastasis” annually who may benefit from these medicines. The company linked the approvals to treatment needs in osteoporosis and bone complications in cancer patients. It did not provide pricing, reimbursement timelines, or market share targets in the text provided. The immediate takeaway is that Biocon now has regulatory clearance for two additional biosimilar products in Canada.

Why Canada matters in Biocon’s biosimilars strategy

Biocon framed Canada as an important North American market for affordable biologics. With Bosaya and Vevzuo approved, the company said it gains market access for two key biosimilar drugs in Canada. The approvals are aligned with Biocon’s broader push to expand global access to biosimilars, a theme repeated across its regulatory announcements. Canada also appears as a recurring geography in the company’s launches and approvals for biosimilars.

Earlier Health Canada clearance: Yesintek and Yesintek IV

Separately, Biocon has previously announced Health Canada approval for Yesintek and Yesintek IV for chronic autoimmune conditions through its subsidiary, Biocon Biologics Ltd. The notice of compliance (NOC) covered Yesintek (ustekinumab injection) and Yesintek IV (ustekinumab for injection, solution for intravenous infusion). Biocon stated these are biosimilars to Stelara and Stelara IV, respectively. The approval was granted on October 17, and Biocon said it paved the way for Canadian commercial availability from mid-October.

Indications and presentations for Yesintek products

Biocon said Yesintek and Yesintek IV are indicated for moderate to severe plaque psoriasis in adults and pediatric patients aged 6-17 years, active psoriatic arthritis in adults, and moderately to severely active Crohn’s disease and ulcerative colitis in adults. The company described these as debilitating autoimmune conditions affecting thousands of Canadians. It also detailed the presentations: Yesintek as a subcutaneous injection in 45 mg/0.5 mL (prefilled syringe and vial) and 90 mg/mL (prefilled syringe). Yesintek IV will be offered as an intravenous solution of 130 mg/26 mL (5 mg/mL). In the company’s communication, Biocon Biologics’ CEO and Managing Director Shreehas Tambe said the approval builds on a successful US launch and strengthens its North America presence.

Another Canada milestone: Yesafili approval and planned July 2025 launch

Biocon Biologics also reported Health Canada granted an NOC for Yesafili (aflibercept), a biosimilar to Eylea, on June 26, 2025. The company said the approval covers vial and prefilled syringe presentations (2 mg/0.05 mL). It added that the approval paved the way for a Canada launch scheduled for July 4, 2025. Biocon Biologics described Yesafili as the first biosimilar to Eylea approved by Health Canada. It also stated that the approval was based on analytical, nonclinical, and clinical data, including a Phase 3 INSIGHT Study in diabetic macular edema.

What the market did after the immunology approval

In an update linked to the Yesintek approval, Biocon shares were described as “a little changed” on Thursday, October 23, after the company announced Health Canada’s NOC for the two ustekinumab biosimilars. No percentage move was provided in the text. For investors tracking the biosimilars segment, the key near-term datapoints in these updates are the sequence of regulatory clearances and the stated commercial timing in Canada.

Snapshot table: Biocon group approvals referenced in the updates

Portfolio context Biocon has shared

Across the releases, Biocon Biologics described itself as a fully integrated global biosimilars company and a subsidiary of Biocon Ltd. It said it serves over 6.0 million patients across 120+ countries by enabling access to biosimilars. It also stated it has commercialized biosimilars in advanced markets including the US, Europe, Australia, Canada, and Japan. The company also cited a pipeline of 20 biosimilar assets spanning diabetology, oncology, immunology, ophthalmology, bone health, and other non-communicable diseases.

What to watch next

For Bosaya and Vevzuo, the April 3, 2026 Health Canada approvals establish the regulatory foundation for Canada sales, but the provided text does not specify a launch date or product presentation details. For Yesintek and Yesintek IV, Biocon has already pointed to commercial availability from mid-October following the October 17 NOC. For Yesafili, the company has tied the approval to a specific planned launch date of July 4, 2025. Investors will likely monitor subsequent company updates for Canada rollout details, including supply readiness and commercial execution timelines for the newly approved denosumab biosimilars.